Expected Moves

Oct 12, 2026→Oct 19, 2026

Nov 20, 2026→Nov 30, 2026

Risk window for a dilutive equity raise or debt restructuring to address severe cash burn and elevated leverage.

Jan 25, 2027→Feb 1, 2027

Preliminary guidance on full-year 2026 profitability, biological asset fair value adjustments, and balance sheet health.

Mar 25, 2027→Apr 5, 2027

Audited full-year results detailing the extent of cyclical margin damage and forward capital expenditure plans.

May 12, 2027→May 19, 2027

First quarter operating metrics providing early visibility into 2027 cash flow generation and margin recovery.